Vetmulin 450 Mg/G Granules For Use In Drinking Water For Pigs, Chickens And Turkeys
Revised: May 2016
AN. 01370/2014
4.9 |
Amount(s) to be administered and administration route For oral administration through the drinking water. Chickens: 25 mg tiamulin hydrogen fumarate per kg bodyweight per day (equivalent to 5.5g of the product per 100 kg bw per day) for 3 to 5 consecutive days. Turkeys: 40 mg tiamulin hydrogen fumarate per kg bodyweight per day (equivalent to 8.9g of the product per 100 kg bw per day) for 3 to 5 consecutive days. Pigs: Swine dysentery caused by Brachyspira hyodysenteriae: 8.8 mg tiamulin hydrogen fumarate per kg bodyweight per day (equivalent to 1.9 g of the product per 100 kg bw per day) for 5 consecutive days. Enzootic pneumonia caused by Mycoplasma hyopneumoniae 15-20 mg tiamulin hydrogen fumarate per kg bodyweight per day (equivalent to 3.3-4.4 g of the product per 100 kg bw per day) for 5 consecutive days. The uptake of medicated water depends on the actual body weight, the water consumption, the clinical condition of the animals, the environment, the age and the kind of feed provided. In order to obtain the correct dosage, the concentration of tiamulin should be calculated, as follows:
To ensure a correct dosage body weight should be determined as accurately as possible to avoid underdosing. Use suitably calibrated weighing equipment to weigh the necessary amount of product. The product can be added directly to the required volume of drinking water or a concentrated solution can be prepared to be diluted to the final concentration afterwards. The maximum solubility of the product is 10 gram/liter. Medicated drinking water and stock solutions should be freshly prepared every 24 hours. Do not use rusty receptacles for preparation of the medicated drinking water. The medicated water should be the only source of drinking water for the animals for the entire duration of the treatment period. After the end of the medication period, the water supply system should be cleaned appropriately to avoid intake of sub-therapeutic amounts of the active substance. Water intake may be depressed during the administration of tiamulin to birds. It appears to be concentration dependent with 0.025% tiamulin reducing intake by approximately 15%. Water intake should be monitored at frequent intervals during medication. If there is no response to treatment within 3 days, the diagnosis should be re-considered and treatment should be changed, if necessary. |
|||||||
4.10 |
Overdose (symptoms, emergency procedures, antidotes), if necessary Chickens and turkeys: Tiamulin hydrogen fumarate has a relatively high therapeutic index in birds. The probability of an overdose is low since water intake, and therefore tiamulin intake, is reduced at high doses. The LD50 is 1290 mg/kg in chickens and is 840 mg/kg in turkeys. The clinical signs of toxicity in chickens are vocalisation, clonic cramps and lying in a lateral position. Signs in turkeys are: clonic cramps, lateral or dorsal lying position, salivation and ptosis. Pigs: A single oral dose of 100 mg/kg BW caused hyperpnoea and abdominal complaints in pigs. At a dose of 150 mg/kg the only effects on the central nerve system was lethargy. A dose of 55 mg/kg during 14 days caused increased salivation and a mild irritation of the stomach. Tiamulin hydrogen fumarate has a relatively high therapeutic index in pigs. The minimum lethal dose has not been established in pigs. If suspected adverse reactions do occur due to overdose, the medication should be discontinued and appropriate symptomatic treatment should be initiated. |
|||||||
4.11 |
Withdrawal period(s) Pigs Meat and offal: 5 days Chickens Meat and offal: 3 days Eggs: Zero days Turkeys Meat and offal: 5 days |
|||||||
|
|
|||||||
5. |
PHARMACOLOGICAL OR IMMUNOLOGICAL PROPERTIES |
|||||||
|
|
|||||||
|
ATC Vet Code: QJ01XQ01 Pharmacotherapeutic group: Antibacterials for systemic use Pleuromutilins |
5.1 |
Pharmacodynamic properties Tiamulin hydrogen fumarate is a semi-synthetic diterpene antibiotic. The mode of action is by inhibition of ribosomal protein synthesis.It is a bacteriostatic antibiotic and the spectrum of activity includes: mycoplasma and spirochetes, in particular Brachyspira hyodysenteriae Tiamulin is bacteriostatic at therapeutic concentrations and has been shown to act at the 70S ribosome. The primary binding site is on the 50S subunit and there is possibly a secondary site where the 50S and 30S subunits join. Tiamulin appears to inhibit microbial protein production by producing biochemically inactive initiation complexes, which prevent elongation of the polypeptide chain. In vitro research has shown that resistant bacterial mutants can be created through multi step resistance. Development of resistance in mycoplasmas is slower. Resistance against B. hyodysenteriae has been seen, and can vary geographically. Cross resistance between tiamulin and tylosin tartrate has been reported: micro-organisms that are resistant for tiamulin, are also resistant for tylosin tartrate, but not vice versa. Resistance in Brachyspirae hyodysenteriae can be caused by a point mutation in the 23S rRna gene. |
|
|
5.2 |
Pharmacokinetic particulars Tiamulin is well absorbed from the gastrointestinal tract of chickens and turkeys. Chicken After the oral administration of 25 mg tiamulin/kg BW, a Cmax of 1.7 µg/ml was measured after 4 hours (tmax). After the administration of medicated drinking water at 250 ppm (250 mg/L tiamulin hydrogen fumarate) to chickens during 48 hours, average concentrations in the serum were 0.78 µg/ml (0.45 - 1.4 µg/ml). There is a very good distribution in the tissues. Approximately 50% (45% - 52%) of the tiamulin is bound to serum proteins. Tiamulin is rapidly metabolised in the liver (hydroxylation, de-alkalysation, hydrolysis). The excretion is through the bile and faeces (55-65%). The remainder is excreted through the urine. The elimination is biphasic: more than 99% is excreted within 24 hours, while the remaining 1% is not excreted until 6 to 8 days. Turkey After the oral administration of 25 mg tiamulin/kg BW, a Cmax of 1.08 µg/ml was measured after 4 hours (tmax). After the administration of medicated drinking water at 250 ppm (250 mg/L tiamulin hydrogen fumarate) to turkeys, average concentrations in the serum were 0.36 µg/ml (0.22 - 0.5 µg/ml). Pigs Tiamulin is well absorbed from the gastrointestinal tract of pigs. 2-4 hours (tmax) after the oral administration of 10 mg tiamulin/kg BW, a Cmax of 1 µg/ml was measured. There is a very good distribution in the tissues. There is accumulation in lungs and in the colon. 30-50% of the tiamulin is bound to serum proteins. Tiamulin is rapidly metabolised in the liver (hydroxylation, de-alkalysation, hydrolysis). At least 16, biologically inactive metabolites have been identified. The excretion is through the bile and faeces (70-85%). The remainder is excreted through the urine (15-30%). |
5.3 |
Environmental properties |
|
Tiamulin hydrogen fumarate is persistent in soils |
6. |
PHARMACEUTICAL PARTICULARS |
|
|
6.1 |
List of excipients Povidone Lactose monohydrate |
|
|
6.2 |
Incompatibilities In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal product. |
|
|
6.3 |
Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 2 years. Shelf life after first opening the immediate packaging: 3 months. Shelf life after dilution or reconstitution according to directions: 24 hours. |
|
|
6.4 |
Special precautions for storage Do not refrigerate or freeze. Store in original container. |
|
|
6.5 |
Nature and composition of immediate packaging Block bottomed zipped 1 kg bag of polyethylene terephthalate/aluminium/low density Polyethylene. |
|
|
6.6 |
Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements |
|
|
7. |
MARKETING AUTHORISATION HOLDER |
|
|
|
Huvepharma N.V. Uitbreidingstraat 80 Antwerpen B-2600 Belgium |
8. |
MARKETING AUTHORISATION NUMBER Vm 30282/4002 |
|
|
9. |
DATE OF FIRST AUTHORISATION 19 March 2009 |
|
|
10. |
DATE OF REVISION OF THE TEXT May 2016 24 May 2016 |
Page 7 of 7